Redirected vaccine imprinting by co-administration of COVID-19 and influenza vaccines

Boyton, Rosemary J.; Altmann, Daniel M.

doi:10.1016/j.lanepe.2023.100644

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, so far only China (CanSino-Convidecia Air) and India (Bharat Biotech-iNCOVACC) have approved mucosal vaccines against SARS-CoV-2. The development of combination mucosal vaccines targeting conserved antigens from multiple pathogens like SARS-CoV-2, seasonal influenza viruses, and RSV, although challenging, may be a viable annual/semiannual option for the prevention of future pandemics [22].…”

Section: Introductionmentioning

confidence: 99%

Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens

Dotiwala,

Upadhyay

2023

Vaccines

View full text Add to dashboard Cite

Inducing humoral and cytotoxic mucosal immunity at the sites of pathogen entry has the potential to prevent the infection from getting established. This is different from systemic vaccination, which protects against the development of systemic symptoms. The field of mucosal vaccination has seen fewer technological advances compared to nucleic acid and subunit vaccine advances for injectable vaccine platforms. The advent of the next-generation adenoviral vectors has given a boost to mucosal vaccine research. Basic research into the mechanisms regulating innate and adaptive mucosal immunity and the discovery of effective and safe mucosal vaccine adjuvants will continue to improve mucosal vaccine design. The results from clinical trials of inhaled COVID-19 vaccines demonstrate their ability to induce the proliferation of cytotoxic T cells and the production of secreted IgA and IgG antibodies locally, unlike intramuscular vaccinations. However, these mucosal vaccines induce systemic immune responses at par with systemic vaccinations. This review summarizes the function of the respiratory mucosa-associated lymphoid tissue and the advantages that the adenoviral vectors provide as inhaled vaccine platforms.

show abstract

Section: Introductionmentioning

confidence: 99%